Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Soufflé Therapeutics Rises with $200M Series A and Big Pharma Partnerships

Soufflé Therapeutics Rises with $200M Series A and Big Pharma Partnerships

A new player in the RNA therapeutics space has emerged with substantial financial backing and pharmaceutical industry support. Soufflé Therapeutics, co-founded by Moderna pioneer Robert Langer, has announced a $200 million series A funding round and partnerships with major pharmaceutical companies, positioning itself as a significant force in the development of targeted siRNA medicines.

NoahAI News10/8/2025
AstraZeneca's Baxdrostat Shows Promise in Phase 3 Hypertension Trial

AstraZeneca's Baxdrostat Shows Promise in Phase 3 Hypertension Trial

AstraZeneca has announced positive results from its phase 3 Bax24 trial for baxdrostat, a novel aldosterone synthase inhibitor aimed at treating treatment-resistant hypertension. The study's success marks a significant milestone for the pharmaceutical giant, potentially strengthening its position in the competitive blood pressure medication market.

NoahAI News10/7/2025
FDA Lifts Clinical Hold on Neurizon's ALS Drug, Paving Way for Human Trials

FDA Lifts Clinical Hold on Neurizon's ALS Drug, Paving Way for Human Trials

The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on Neurizon's investigational drug for amyotrophic lateral sclerosis (ALS), allowing the Melbourne-based biotech company to proceed with human trials. The decision comes after months of delays and additional data submissions, highlighting both the challenges in ALS drug development and the current strains on regulatory processes.

NoahAI News10/7/2025
Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Market Pressures

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Market Pressures

The pharmaceutical and biotech sectors are experiencing a wave of workforce reductions as companies reevaluate their priorities and respond to challenging market conditions. Major players and smaller firms alike are implementing cost-cutting measures, with layoffs affecting thousands of employees across research, manufacturing, and commercial operations.

NoahAI News10/7/2025
Rocket Pharmaceuticals Withdraws FDA Application for Fanconi Anemia Gene Therapy

Rocket Pharmaceuticals Withdraws FDA Application for Fanconi Anemia Gene Therapy

In a significant development for the gene therapy landscape, Rocket Pharmaceuticals has voluntarily withdrawn its Biologics License Application (BLA) for mozafancogene autotemcel, a potential treatment for the rare blood disorder Fanconi anemia. This decision, announced in an SEC filing on October 6, 2025, marks a strategic shift for the New Jersey-based biotech company as it realigns its pipeline priorities.

NoahAI News10/7/2025
Atlantic Health and Saint Peter's Healthcare System Cancel Merger Plans Amid Shifting Healthcare Landscape

Atlantic Health and Saint Peter's Healthcare System Cancel Merger Plans Amid Shifting Healthcare Landscape

Atlantic Health and Saint Peter's Healthcare System, two prominent New Jersey nonprofit healthcare providers, have mutually agreed to terminate their planned merger. The decision, announced on October 6, 2025, comes in response to evolving trends in the national healthcare sector.

NoahAI News10/7/2025
Revvity and Sanofi Partner on Early Type 1 Diabetes Detection; Kihealth Secures Funding for Diabetes Test

Revvity and Sanofi Partner on Early Type 1 Diabetes Detection; Kihealth Secures Funding for Diabetes Test

Revvity, a Massachusetts-based diagnostics company, has announced a collaboration with pharmaceutical giant Sanofi to develop an advanced screening test for early-stage Type 1 diabetes. Meanwhile, Kihealth has raised $5 million in seed funding to support the commercial rollout of its innovative diabetes detection test.

NoahAI News10/7/2025
TCG Crossover Secures $1.3B for Third Fund, Bolstering Biotech Investment Portfolio

TCG Crossover Secures $1.3B for Third Fund, Bolstering Biotech Investment Portfolio

TCG Crossover (TCGX), a prominent bicoastal life sciences investment firm, has successfully closed its third fund, raising $1.3 billion and bringing its total capital to an impressive $3.1 billion. This latest financial milestone, announced on October 6, 2025, underscores the firm's growing influence in the biotech investment landscape and its commitment to backing innovative medical advancements.

NoahAI News10/7/2025
AstraZeneca and Daiichi Sankyo's Datroway Shows Promise in Triple-Negative Breast Cancer

AstraZeneca and Daiichi Sankyo's Datroway Shows Promise in Triple-Negative Breast Cancer

AstraZeneca and Daiichi Sankyo have announced groundbreaking results for their antibody-drug conjugate (ADC) Datroway in the treatment of triple-negative breast cancer (TNBC). The drug has demonstrated significant improvements in overall survival and progression-free survival compared to standard chemotherapy, potentially marking a turning point in the treatment of this aggressive form of cancer.

NoahAI News10/7/2025
Eli Lilly Commits Over $1 Billion to Boost Manufacturing Partnerships in India

Eli Lilly Commits Over $1 Billion to Boost Manufacturing Partnerships in India

Eli Lilly, the Indianapolis-based pharmaceutical giant, has announced plans to invest more than $1 billion in its Indian operations, focusing on expanding contract manufacturing partnerships to increase the supply of key medicines. This significant move comes as part of the company's broader strategy to strengthen its global manufacturing network and address growing demand for its products across various therapeutic areas.

NoahAI News10/7/2025
Skye Bioscience's Obesity Drug Nimacimab Falls Short in Key Study

Skye Bioscience's Obesity Drug Nimacimab Falls Short in Key Study

Skye Bioscience, a San Diego-based biotechnology company, faced a significant setback as its experimental weight loss drug nimacimab failed to meet expectations in a mid-stage clinical trial. The news, announced on Monday, led to a dramatic decline in the company's stock price, with shares plummeting by nearly two-thirds to less than $2 in early trading.

NoahAI News10/7/2025
Gilead Extends Biktarvy's Market Exclusivity to 2036, Strengthening Its HIV Portfolio

Gilead Extends Biktarvy's Market Exclusivity to 2036, Strengthening Its HIV Portfolio

Gilead Sciences has successfully negotiated patent settlements with three generic drug manufacturers, effectively extending the market exclusivity of its flagship HIV treatment, Biktarvy, until April 1, 2036. This development marks a significant win for the pharmaceutical giant, pushing back the entry of generic competitors by approximately three years from the previously anticipated date.

NoahAI News10/7/2025
«1...343536...67»